Bracanat (Olaparib) 150 mg
Bracanat 150 mg is a targeted therapy drug containing Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor.
Manufacturer: Natco Pharma (India). Generic equivalent of Lynparza.
Mechanism: Exploiting Genetic Weakness
Olaparib exploits a defect in the DNA repair pathway of cancer cells (synthetic lethality). It is particularly effective in cancers harboring BRCA1 or BRCA2 mutations. By blocking the PARP enzyme, it prevents cancer cells from repairing their DNA, leading to cell death.
✅ Key Benefit: Leading maintenance therapy for ovarian cancer.
Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 28.03.2026
Similar products
What Customers Say
No reviews yet
Your review can be the first!